Navigation Links
Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
Date:10/3/2007

SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at BIO InvestorForum 2007 on Wednesday, October 10, 2007, at 11:45 a.m. PDT (2:45 p.m. EDT). The conference is being held at The Palace Hotel in San Francisco.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. will present an overview of Anadys and an update on its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be archived until October 24, 2007.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by developing and commercializing novel small molecule medicines for the treatment of hepatitis C virus (HCV) infection and cancer. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop and commercialize novel small molecule medicines
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...s of the European Association of Echocardiography ... of Cardiology, where techniques of non-invasive d... reports will be presented at this year,s Congress...f this new technology. , Now, with such rapid d...t non-invasive imaging will gain more importance i...
(Date:12/2/2009)...has been a top name in the medical supply industry...ts, professional staff, and a keen understanding o...s established itself as a provider of ground ambul...id supplies distributor. The distinguished history...s next phase with the redesign and launch of its w...
(Date:12/2/2009)...re than 900 runners and walkers from Las Vegas and...the Rock ‘n’ Roll Las Vegas Half Marat...on for the Crohn,s & Colitis Foundation throug...ge (www.ccteamchallenge). As the official charity ...ucation, and support initiatives to benefit the 1....
(Date:12/2/2009)...e/ -- In response to rising suicide and divorce ra...ofit ministry dedicated to supporting marriages an...#174; marriage conference at a significant discou...3 at the Grand Hyatt Atlanta in Buckhead (3300 Pea...age getaway aimed at strengthening healthy marriag...
(Date:12/2/2009)...on Post Highlights Dangers ,, WASHINGTON, D...c bishops have their way, many medical treatments ...be under threat. The pressure that the US bishops...e reform has been widely reported. An ad in this m...act if that pressure to influence healthcare polic...
Breaking Medicine News(10 mins):Health News:Media alert: EUROECHO 2009 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4Health News:FamilyLife Supports Military Marriages in Atlanta 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2
...ital in 25 Years, DENVER, March 6 Global Med Tec...nternational e-Health, medical,information technol...hnologies(R) division has signed an agreement with...isclosed., (Logo: http://www.newscom.com/cgi-bin...
...uces acrylamide levels by up to 23% , , TH...es in water before frying cuts down on the formati...a new, British study. , Acrylamide is created when...me research has suggested that acrylamide, which i...
...adiosurgical Treatments, SUNNYVALE, Calif., March...l leader in the field of radiosurgery,announced to...ded that the,CyberKnife(R) Robotic Radiosurgery Sy...its -- which,combine radiotherapy and radiosurgery...
...Centers, Inc.,("GNC" or the "Company"), the larges...ents, today reported its financial results for the...utrition Centers, Inc. is an indirect wholly-owned...such, the,financial results presented in this pres...
...echnology, Inc. (OTC Bulletin Board: CSBR), a deve...ay its third quarter financial results.,Full detai...e in the,Company,s Form 10-QSB at http://www.sec....of $37,198 and loss of $0.00 per share for the com...
...rk Inc.,(Nasdaq: ORCH ), a leading worldwide prov...ted its financial results for the fourth quarter a...ially flat at $15.0 million for the fourth,quarter...r the full year of 2006. Revenues for the fourth q...
Other Medicine News:Health News:Newest Hospital in New England Signs Agreement With Global Med Technologies(R), Inc. 2Health News:Newest Hospital in New England Signs Agreement With Global Med Technologies(R), Inc. 3Health News:Soaking Potatoes Before Frying Cuts Suspected Carcinogen 2Health News:Independent Survey Names CyberKnife(R) System Most Widely Used Extracranial Radiosurgery Technology 2Health News:Independent Survey Names CyberKnife(R) System Most Widely Used Extracranial Radiosurgery Technology 3Health News:Independent Survey Names CyberKnife(R) System Most Widely Used Extracranial Radiosurgery Technology 4Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 2Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 3Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 4Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 5Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 6Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 7Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 8Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 9Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 10Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 11Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 2Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 3Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 9
(Date:12/2/2009)... ABBOTT PARK, Ill., Dec. 2 /PRNewswire-FirstCall/ ...acterizing a vast array of microorganisms has been...Scientist magazine. A panel of expert judges eva...to determine the year,s top innovations, with the ...ue and online at www.the-scien t ist.com/top10...
(Date:12/2/2009)... , LEXINGTON, Mass. and HEIDELBERG, Germany, D...ecognized as one of the winners of the "Top 10 Inn... company,s automated sequence capture technology f...its exceptional combinations of invention, vision ...el of expert judges to evaluate a broad range of l...
(Date:12/2/2009)..., KNOXVILLE, Tenn., Dec. 2 Team...a division of the nation,s largest provider of hos... signed two contracts to provide teleradiology ser...s. ,, An agreement signed with UpState Carolina...w TeamHealth Teleradiology to provide services for...
Breaking Medicine Technology:Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist 2The Scientist Magazine Recognizes febit's HybSelect(TM) Among the Winners of 'Top 10 Innovations of 2009' 2TeamHealth Teleradiology Announces New Contracts in South Carolina and Illinois 2Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Pri 60445 1Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Pri 60445 2Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Pri 60445 3Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Pri 60445 4Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Pri 60445 5Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Pri 60445 6Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Pri 60445 7Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Pri 60445 8Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Pri 60445 9Company C Donates 2440 000 To Fight Breast Cancer 60442 1Company C Donates 2440 000 To Fight Breast Cancer 60442 2AARP Commends Legislature For Saving Critical Health Care Program 60438 1
...tal trial suggests that ofatumumab has activity in...dard treatments , , , PHILADELPHIA, Dec. 8...announced today positive results from a pivotal tr...fatumumab) in the treatment of refractory chronic ...e the potential of ofatumumab for heavily pre-trea...
.... 8 Results published online today in the,New Eng... most clinically,advanced malaria vaccine candidat...gnificant protection against malaria. Two separate...and support the ongoing efforts, pending,regulator...oSmithKline,(NYSE: GSK ) Biologicals, RTS,S/AS v...
Other Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa 2Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa 3Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa 4Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa 5Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa 6Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa 7Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa 8
Pulley for Cable, Spare part for ATA100
Knife Raising Block
Tilt Adapter +- 8 Degrees
...s a look that is revolutionary, a feel that is mar...that will please the most demanding of users. Bas...breaking new ground with an innovative design the ... of your laboratory cutting and sectioning needs. ...
Medicine Products: